Published in Schizophr Res on December 01, 2004
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets (2006) 1.78
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) (2008) 1.46
Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry (2008) 1.08
Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortex. Neuropsychopharmacology (2011) 0.92
Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand? Eur Arch Psychiatry Clin Neurosci (2011) 0.90
GSK-3β activity and hyperdopamine-dependent behaviors. Neurosci Biobehav Rev (2010) 0.88
Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment. Eur Arch Psychiatry Clin Neurosci (2014) 0.82
Copy number variation of the SELENBP1 gene in schizophrenia. Behav Brain Funct (2010) 0.82
Region-specific dysregulation of glycogen synthase kinase-3β and β-catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia. Bipolar Disord (2014) 0.80
Dopaminergic intracellular signal integrating proteins: relevance to schizophrenia. Dialogues Clin Neurosci (2006) 0.79
Elevated urinary ADAM12 protein levels in lithium-treated bipolar patients. J Neural Transm (Vienna) (2006) 0.79
Neurodevelopment in schizophrenia: the role of the wnt pathways. Curr Neuropharmacol (2013) 0.77
Integrative transcriptome network analysis of iPSC-derived neurons from schizophrenia and schizoaffective disorder patients with 22q11.2 deletion. BMC Syst Biol (2016) 0.76
Radiosynthesis and In Vivo Evaluation of [11C]A1070722, a High Affinity GSK-3 PET Tracer in Primate Brain. ACS Chem Neurosci (2017) 0.75
Major depressive disorder. N Engl J Med (2008) 6.61
Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res (2010) 1.83
A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res (2006) 1.67
Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology (2005) 1.67
Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res (2008) 1.46
Effect of prolonged phenytoin administration on rat brain gene expression assessed by DNA microarrays. Exp Biol Med (Maywood) (2010) 1.44
Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr Bull (2008) 1.37
Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res (2006) 1.34
Valproate decreases inositol biosynthesis. Biol Psychiatry (2004) 1.33
A family-based association study and gene expression analyses of netrin-G1 and -G2 genes in schizophrenia. Biol Psychiatry (2005) 1.20
Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia. Aust N Z J Psychiatry (2007) 1.13
GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol (2002) 1.13
Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav Pharmacol (2008) 1.12
Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry (2007) 1.09
Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. Hum Mol Genet (2006) 1.07
Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis. Science (2011) 1.06
Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol (2005) 1.05
Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast. J Biol Chem (2004) 1.04
Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem (2008) 1.03
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos (2011) 1.02
Search for a common mechanism of mood stabilizers. Biochem Pharmacol (2003) 1.02
Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm (2013) 1.00
Homozygote inositol transporter knockout mice show a lithium-like phenotype. Bipolar Disord (2008) 1.00
Evidence for disruption of sphingolipid metabolism in schizophrenia. J Neurosci Res (2009) 0.99
Normal human aging and early-stage schizophrenia share common molecular profiles. Aging Cell (2009) 0.99
Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.99
Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol (2008) 0.97
IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacology (2007) 0.96
Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int J Neuropsychopharmacol (2012) 0.95
Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. Synapse (2007) 0.95
Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol (2010) 0.95
The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res (2010) 0.94
Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep (2007) 0.94
Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord (2010) 0.93
Region and diagnosis-specific changes in synaptic proteins in schizophrenia and bipolar I disorder. Psychiatry Res (2010) 0.92
Lymphoblast and brain expression of AHI1 and the novel primate-specific gene, C6orf217, in schizophrenia and bipolar disorder. Schizophr Res (2010) 0.90
Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype. Biol Psychiatry (2003) 0.90
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. Bioorg Med Chem Lett (2007) 0.90
Recent advances in postmortem pathology and neurochemistry in schizophrenia. Curr Opin Psychiatry (2009) 0.89
Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci (2013) 0.89
GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res (2002) 0.87
Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype. Neuropsychopharmacology (2009) 0.87
Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Front Cell Neurosci (2013) 0.87
Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophr Res (2007) 0.87
Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Rev Neurother (2009) 0.87
Lithium preferentially inhibits adenylyl cyclase V and VII isoforms. Int J Neuropsychopharmacol (2008) 0.86
The effect of lithium on expression of genes for inositol biosynthetic enzymes in mouse hippocampus; a comparison with the yeast model. Brain Res Mol Brain Res (2003) 0.86
Individual differences and evidence-based psychopharmacology. BMC Med (2012) 0.86
Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. Biochem Pharmacol (2006) 0.85
SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. Mol Genet Metab (2006) 0.85
Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology (2006) 0.85
Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. Aust N Z J Psychiatry (2006) 0.85
No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. Life Sci (2005) 0.84
Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. Aust N Z J Psychiatry (2010) 0.84
Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. Biol Psychiatry (2005) 0.84
Glycogen synthase kinase (GSK)-3beta levels and activity in a neurodevelopmental rat model of schizophrenia. Brain Res Dev Brain Res (2003) 0.83
Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. Bipolar Disord (2009) 0.83
Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. Psychiatry Res (2012) 0.83
Imidazopyridines: a novel class of hNav1.7 channel blockers. Bioorg Med Chem Lett (2008) 0.83
Specificity of mood stabilizer action on neuronal growth cones. Bipolar Disord (2007) 0.83
Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci Lett (2005) 0.82
Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels. Int J Neuropsychopharmacol (1999) 0.82
Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int J Neuropsychopharmacol (2007) 0.82
Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry (2003) 0.82
Decreased Neuregulin 1 C-terminal fragment in Brodmann's area 6 of patients with schizophrenia. Schizophr Res (2010) 0.82
Copy number variation of the SELENBP1 gene in schizophrenia. Behav Brain Funct (2010) 0.82
Evaluation of homogenization techniques for the preparation of mouse tissue samples to support drug discovery. Bioanalysis (2011) 0.82
Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur Neuropsychopharmacol (2005) 0.81
Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank. Int J Neuropsychopharmacol (2013) 0.81
Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. Brain Res Mol Brain Res (2004) 0.81
Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophr Res (2006) 0.81
Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Mol Cell Neurosci (2010) 0.81
Lack of effect of mood stabilizers or neuroleptics on GSK-3 protein levels and GSK-3 activity. Int J Neuropsychopharmacol (2003) 0.81
Mitochondrial DNA HV lineage increases the susceptibility to schizophrenia among Israeli Arabs. Schizophr Res (2007) 0.81
Abnormal hippocampal distribution of TDP-43 in patients with-late onset psychosis. Aust N Z J Psychiatry (2009) 0.81
Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. Psychiatry Res (2006) 0.81
Survey of the performance of commercial dose calibrators for measurement of ¹²³I activity. J Nucl Med Technol (2011) 0.80
Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. Psychiatry Res (2007) 0.80
Interaction of calbindin D28k and inositol monophosphatase in human postmortem cortex: possible implications for bipolar disorder. Bipolar Disord (2005) 0.80
Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. Drug Metab Dispos (2007) 0.80
Chronic lithium treatment affects rat brain and serum dehydroepiandrosterone (DHEA) and DHEA-sulphate (DHEA-S) levels. Int J Neuropsychopharmacol (2004) 0.80
Mitochondrial complex I subunits are altered in rats with neonatal ventral hippocampal damage but not in rats exposed to oxygen restriction at neonatal age. J Mol Neurosci (2008) 0.80
Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects. Schizophr Res (2004) 0.80
The Cholinergic System: An Emerging Drug Target for Schizophrenia. Curr Pharm Des (2016) 0.80
Evaluation of treatment in 35 cases of bipolar suicide. Aust N Z J Psychiatry (2009) 0.79
Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder. Neurosci Lett (2009) 0.79
Normobaric hyperoxia treatment of schizophrenia. J Clin Psychopharmacol (2012) 0.79
Postmortem brain calcineurin protein levels in schizophrenia patients are not different from controls. Schizophr Res (2006) 0.79